NCT04221269|Completed
Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders
CLASP-S
Post-Hospital Suicide Prevention Intervention for Patients With Schizophrenia-Spectrum Disorders
Loading search results
CLASP-S
Post-Hospital Suicide Prevention Intervention for Patients With Schizophrenia-Spectrum Disorders
Sponsor study identifier
interventional
30
1 country
1
Study Start
December 1, 2020
Actual (reported)Primary Completion
June 1, 2023
Actual (reported)Study Completion
June 1, 2023
Actual (reported)The current project is a pilot randomized controlled trial to test the Coping Long-term with Active Suicide Program for schizophrenia-spectrum disorders (CLASP-S) for patients following a psychiatric hospitalization. Participants will be assigned to enhanced treatment as usual (ETAU) alone vs CLASP-S plus ETAU. Participants complete assessments at baseline during their psychiatric hospitalization and at 3 months (mid-treatment) and 6 months (post-treatment) following discharge. The primary aim is to assess the feasibility and acceptability of CLASP-S. The secondary aim is to estimate the effects of CLASP-S on reducing suicidal thoughts and behaviors relative to ETAU.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 1, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 6, 2020
Actual (reported)January 9, 2020
Actual (reported)December 1, 2020
Actual (reported)June 1, 2023
Actual (reported)June 1, 2023
Actual (reported)Client Satisfaction Questionnaire
The Client Satisfaction Questionnaire is a self-report measure of patient satisfaction with treatment. The total score (sum of items) will be used and ranges from 8 to 32 with increased scores indicating greater satisfaction with treatment.
6 months
Columbia Suicide Severity Rating Scale
6 months
Participants assigned to Enhanced Treatment as Usual (ETAU) alone will receive unrestricted routine care in the community. Assessment feedback reports will be sent to participants' community providers at baseline, 3 months, and 6 months for care coordination.
Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.
Routine community care plus assessment feedback reports to clinicians.
Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.
Butler Hospital
Providence, Rhode Island, 02906, United States
Brandon Gaudiano, PhD
Butler Hospital
30 participants (actual enrollment reported by the registry).
First Submitted
January 6, 2020
First Posted
January 9, 2020
Study Start
December 1, 2020
Actual (reported)Neural Mechanisms and Predictors of an Ultra-Brief Suicide Prevention Strategy
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
June 1, 2023
Actual (reported)Study Completion
June 1, 2023
Actual (reported)Last Updated
July 11, 2023
Record last verified: 2023-07
After all data have been collected and the results of the studies published, de-identified data will be made available to other qualified researchers on request.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: